Nakazato Tetsuya, Suzuki Yutaka, Tanaka Ryota, Abe Nobutsugu, Masaki Tadahiko, Mori Toshiyuki, Ohkura Yasuo, Sugiyama Masanori
Pancreas. 2018 Mar;47(3):291-295. doi: 10.1097/MPA.0000000000001002.
Reprimo gene is a cytoplasmic protein belonging to a family of molecules controlled by p53 that inhibits cell cycle progression. Ectopic expression of Reprimo results in cell cycle arrest at the G2 phase. The aim of this study was to investigate the impact of Reprimo expression on tumorigenesis of intraductal papillary mucinous neoplasm (IPMN).
Thirty-seven surgical cases of IPMN were collected retrospectively. Twenty-eight patients had benign IPMNs (low-grade dysplasia, n = 18; intermediate-grade dysplasia, n = 10), and the remaining 9 had malignant IPMNs (high-grade dysplasia, n = 4; invasive carcinoma, n = 5). DNA from tumor samples was extracted. DNA methylation patterns of Reprimo were determined by the methods of methylation-specific polymerase chain reaction and immunohistochemistry. The methylation status of Reprimo was compared between benign IPMNs and malignant IPMNs.
The incidence of aberrant DNA methylation of Reprimo was significantly higher in malignant IPMNs than in benign IPMNs (78% vs 32%, P = 0.016). Furthermore, the incidence of immunohistochemical Reprimo expression was significantly lower in malignant IPMNs than in benign IPMNs (22% vs 82%, P = 0.002).
Reprimo methylation was found more frequently in malignant IPMNs. Reprimo methylation is involved in malignant transformation of IPMNs.
Reprimo基因是一种细胞质蛋白,属于受p53调控的分子家族,可抑制细胞周期进程。Reprimo的异位表达导致细胞周期停滞于G2期。本研究旨在探讨Reprimo表达对导管内乳头状黏液性肿瘤(IPMN)肿瘤发生的影响。
回顾性收集37例IPMN手术病例。28例患者为良性IPMN(低级别异型增生,n = 18;中级别异型增生,n = 10),其余9例为恶性IPMN(高级别异型增生,n = 4;浸润性癌,n = 5)。提取肿瘤样本的DNA。采用甲基化特异性聚合酶链反应和免疫组化方法测定Reprimo的DNA甲基化模式。比较良性IPMN和恶性IPMN中Reprimo的甲基化状态。
恶性IPMN中Reprimo异常DNA甲基化的发生率显著高于良性IPMN(78%对32%,P = 0.016)。此外,恶性IPMN中免疫组化Reprimo表达的发生率显著低于良性IPMN(22%对82%,P = 0.002)。
在恶性IPMN中更频繁地发现Reprimo甲基化。Reprimo甲基化参与IPMN的恶性转化。